[Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
作者信息
Ito Harunobu, Wajima Teruaki, Yamaguchi Masayuki, Mimori Nobuyuki, Sekiguchi Kaneo
出版信息
Nihon Yakurigaku Zasshi. 2010 Nov;136(5):299-308. doi: 10.1254/fpj.136.299.
PMID:21079371
Abstract
摘要
相似文献
1
[Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].二肽基肽酶-4抑制剂维格列汀的临床前及临床研究结果
Nihon Yakurigaku Zasshi. 2010 Nov;136(5):299-308. doi: 10.1254/fpj.136.299.
2
Vildagliptin in clinical practice: a review of literature.维格列汀的临床应用：文献复习。
Expert Opin Pharmacother. 2009 Nov;10(16):2745-57. doi: 10.1517/14656560903302265.
3
Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.二肽基肽酶-IV（DPP-4）抑制剂维格列汀在2型糖尿病管理中的新作用
J Assoc Physicians India. 2011 Apr;59:237-45.
4
Drug evaluation: vildagliptin-metformin single-tablet combination.药物评价：维格列汀-二甲双胍单片复方制剂。
Adv Ther. 2009 Feb;26(2):138-54. doi: 10.1007/s12325-009-0010-0. Epub 2009 Mar 19.
5
Vildagliptin: a review of its use in type 2 diabetes mellitus.维格列汀：用于 2 型糖尿病的评价。
Drugs. 2010 Nov 12;70(16):2089-112. doi: 10.2165/11206370-000000000-00000.
6
Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.长期应用二肽基肽酶-4 抑制剂维格列汀对非肥胖型 2 型糖尿病 Goto-Kakizaki 大鼠胰岛内分泌细胞的影响。
Eur J Pharmacol. 2012 Sep 15;691(1-3):297-306. doi: 10.1016/j.ejphar.2012.07.030. Epub 2012 Jul 20.
7
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].二肽基肽酶-4抑制剂（格列汀类）：一类新型口服抗糖尿病药物
Orv Hetil. 2011 Sep 11;152(37):1471-6. doi: 10.1556/OH.2011.29207.
8
[The value of incretin based therapies].[基于肠促胰岛素的治疗方法的价值]
Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6.
9
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes.维格列汀，一种二肽基肽酶-4 抑制剂，用于治疗 2 型糖尿病。
Expert Opin Drug Metab Toxicol. 2014 Apr;10(4):599-608. doi: 10.1517/17425255.2014.889683. Epub 2014 Feb 19.
10
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.使用二肽基肽酶-4抑制剂维格列汀治疗可改善2型糖尿病患者的空腹胰岛细胞功能。
J Clin Endocrinol Metab. 2009 Jan;94(1):81-8. doi: 10.1210/jc.2008-1135. Epub 2008 Oct 28.
Zotero 插件